Livedoid vasculitis - Vascwlitis Livedoid
Mae Vascwlitis Livedoid (Livedoid vasculitis) yn glefyd croenol cronig a welir yn bennaf mewn merched ifanc a chanol oed. Un acronym a ddefnyddir i ddisgrifio ei nodweddion yw "Wlserau purpurig poenus gyda phatrwm reticular o'r eithafion isaf" (PURPLE). Mae'n gysylltiedig â nifer o afiechydon, gan gynnwys gorbwysedd gwythiennol cronig ac amrywogaethau.
☆ Yng nghanlyniadau Stiftung Warentest 2022 o’r Almaen, roedd boddhad defnyddwyr â ModelDerm ond ychydig yn is nag ymgynghoriadau telefeddygaeth taledig.
Gall fod yng nghwmni poen.
References
Mae Livedoid vasculopathy yn gyflwr croen prin a nodweddir gan wlserau poenus sy'n dod yn ôl ar waelod y coesau o hyd.
Livedoid vasculopathy (LV) is a rare thrombotic vasculopathy of the dermis characterized by painful, relapsing ulcers over the lower extremities. Diagnosis is challenging due to the overlap in clinical appearance and nomenclature with other skin disorders. Treatment selection is complicated by poor understanding of the pathogenesis of LV and lack of robust clinical trials evaluating therapy efficacy. The terminology and pathophysiology of LV are reviewed here, along with its epidemiology, clinical and histologic features, and treatment options. A diagnostic pathway is suggested to guide providers in evaluating for comorbidities, referring to appropriate specialists, and choosing from the available classes of therapy.
Livedoid vasculopathy (LV) is a rare thrombotic vasculopathy of the dermis characterized by painful, relapsing ulcers over the lower extremities. Diagnosis is challenging due to the overlap in clinical appearance and nomenclature with other skin disorders. Treatment selection is complicated by poor understanding of the pathogenesis of LV and lack of robust clinical trials evaluating therapy efficacy. The terminology and pathophysiology of LV are reviewed here, along with its epidemiology, clinical and histologic features, and treatment options. A diagnostic pathway is suggested to guide providers in evaluating for comorbidities, referring to appropriate specialists, and choosing from the available classes of therapy.
Mae Livedoid vasculopathy yn gyflwr croen prin sy'n achosi wlserau cylchol ar waelod y coesau, gan adael creithiau gwelw a elwir yn atrophie blanche ar ôl. Er bod yr union achos yn dal yn aneglur, credir mai mwy o geulo gwaed (hypercoagulability) yw'r prif ffactor, gyda llid yn chwarae rhan eilaidd. Mae'r ffactorau sy'n cyfrannu at geulo yn cynnwys fel a ganlyn - deficiencies in proteins C and S, genetic mutations like factor V Leiden, antithrombin III deficiency, prothrombin gene mutations, high levels of homocysteine. Mewn biopsïau, mae'r cyflwr yn dangos clotiau gwaed y tu mewn i bibellau, waliau llestr yn tewychu, a chreithiau. Mae triniaeth yn cynnwys dull aml-ochrog sy'n canolbwyntio ar atal clotiau gwaed gyda meddyginiaethau fel cyffuriau gwrthblatennau, teneuwyr gwaed, a therapi ffibrinolytig. Gellir defnyddio cyffuriau amrywiol ar gyfer y cyflwr croen hwn - colchicine and hydroxychloroquine, vasodilators, immunosuppressants.
Livedoid vasculopathy is a rare skin condition that causes recurring ulcers on the lower legs, leaving behind pale scars known as atrophie blanche. While the exact cause is still unclear, it's believed that increased blood clotting (hypercoagulability) is the main factor, with inflammation playing a secondary role. Factors contributing to clotting include as follows - deficiencies in proteins C and S, genetic mutations like factor V Leiden, antithrombin III deficiency, prothrombin gene mutations, high levels of homocysteine. In biopsies, the condition shows blood clots inside vessels, thickening of vessel walls, and scarring. Treatment involves a multi-pronged approach focusing on preventing blood clots with medications like anti-platelet drugs, blood thinners, and fibrinolytic therapy. Various drugs can be used for this skin condition - colchicine and hydroxychloroquine, vasodilators, immunosuppressants.
Livedoid vasculopathy is a rare skin condition that causes recurring ulcers on the lower legs, leaving behind pale scars known as atrophie blanche. While the exact cause is still unclear, it's believed that increased blood clotting (hypercoagulability) is the main factor, with inflammation playing a secondary role. Factors contributing to clotting include as follows - deficiencies in proteins C and S, genetic mutations like factor V Leiden, antithrombin III deficiency, prothrombin gene mutations, high levels of homocysteine. In biopsies, the condition shows blood clots inside vessels, thickening of vessel walls, and scarring. Treatment involves a multi-pronged approach focusing on preventing blood clots with medications like anti-platelet drugs, blood thinners, and fibrinolytic therapy. Various drugs can be used for this skin condition - colchicine and hydroxychloroquine, vasodilators, immunosuppressants.
Mae Livedoid vasculopathy yn gyflwr prin lle mae briwiau'n digwydd ar y ddwy goes. Credir bod ffurfio clotiau gwaed mewn pibellau gwaed bach yn cael ei achosi gan fwy o geulo a llai o glotiau'n chwalu, ynghyd â niwed i leinin y llestr. Mae'n fwy cyffredin ymhlith merched, yn enwedig rhwng 15 a 50 oed. Mae rhoi'r gorau i ysmygu, gofalu am glwyfau, a defnyddio meddyginiaethau fel teneuwyr gwaed a chyffuriau gwrthblatennau wedi bod yn effeithiol.
Livedoid vasculopathy is a rare vasculopathy that is typically characterized by bilateral lower limb lesions. Increased thrombotic activity and decreased fibrinolytic activity along with endothelial damage are believed to be the cause of thrombus formation in the capillary vasculature. It is 3 times more common in females than in males, especially in patients between the ages of 15 to 50 years. There is no definite first-line treatment, but general measures like smoking cessation, wound care, and pharmacological measures like anticoagulants and antiplatelets have shown good results.
Livedoid vasculopathy is a rare vasculopathy that is typically characterized by bilateral lower limb lesions. Increased thrombotic activity and decreased fibrinolytic activity along with endothelial damage are believed to be the cause of thrombus formation in the capillary vasculature. It is 3 times more common in females than in males, especially in patients between the ages of 15 to 50 years. There is no definite first-line treatment, but general measures like smoking cessation, wound care, and pharmacological measures like anticoagulants and antiplatelets have shown good results.
